|Senesco Announces FDA Clearance For Investigational New Drug Application. Momenta Announces Study Showing M402 Inhibits Tumor Metastasis.|
|By BioMedReports.com Staff|
|Monday, 20 June 2011 19:22|
Senesco Technologies, Inc. (AMEX:SNT) announced the Company has been told by the FDA that all clinical hold issues have been satisfactorily addressed and the FDA has removed the clinical hold on Senesco’s Investigational New Drug (IND) application.
Senesco was informed by the FDA that it may proceed with its clinical study in multiple myeloma after their supplier provided the requested update to the Drug Master File (DMF) and satisfactorily answered all theFDA questions and concerns. Senesco’s IND for SNS01-T is open.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced results from a preclinical study of its novel oncology drug candidate, M402, were published in the on-line edition of the journal PLoS ONE. PLoS One is the online edition of the scientific journal Public Library of Science.
M402 is a heparan sulfate glycosaminoglycan (HSGAG) mimetic engineered from low molecular weight heparin to have potent activity against multiple factors involved in tumor angiogenesis, progression and metastasis while displaying highly reduced anticoagulant activity. In this study, anti-tumor efficacy was first evaluated in an experimental murine melanoma metastasis model. The data indicated that a single dose of M402 administered prior to tumor inoculation significantly reduced tumor colonization in the lung in a dose-dependent manner, presumably due to inhibiting adhesion of circulating tumor cells to new metastatic sites.
Subsequent immunohistological analysis showed a decrease in microvessel density in both primary tumors and lung metastases in the M402 treated group, suggesting that anti-angiogenesis may contribute to the anti-tumor effect of M402.
Adherex Technologies Inc. (TSX-V: AHX) (PINKSHEETS: ADHXF) (the "Company"), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today announced that Robert Andrade, Chief Financial Officer, will present at the upcoming OneMed Forum NY 2011 Conference on Thursday, June 23 at 10:45 a.m. at the Roosevelt Hotel, 45 East 45th St. New York, NY.
Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN) today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON™ (exenatide extended-release for injectable suspension) and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28.
AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Ephraim Sehayek, M.D. of the Cleveland Clinic has been named to the Company's Scientific Advisory Board.
Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX) today reported that its anti-cancer compound, Kevetrin™, has demonstrated potent anti-tumor activity in the treatment of a pancreatic carcinoma cell line in a xenograft tumor model. After three weeks of studies, results testing Kevetrin™ against Pancreatic Carcinoma Cell line MIA-PaCa-2 showed average tumor volume shrinkage of 67% and a tumor growth delay of greater than 94% with no significant weight loss in the animals.
Clenergen Corporation (OTCQB: CRGE). Clenergen offers strategic clean energy generation and supply of biomass feedstock to address the requirement for renewable and sustainable supplies of electricity.
D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) is pleased to announce that it will offer a sampling of its recently FDA and Health Canada cleared Spring™ Universal Infusion Set, at the American Diabetes Association's 71st Scientific Sessions being held on June 24-28 in San Diego, CA.
Genetic Technologies Limited (ASX: GTG; NASDAQ:GENE), through its North American division, Phenogen Sciences Inc., has launched the new BREVAGen™ genetic test for assessing non-familial breast cancer risk.
Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center.
Medical Marijuana Inc (PINKSHEETS: MJNA) and CannaBANK™ are proud to announce a Memorandum of Understanding to acquire a 50% stake in one of the largest patient recommendation sources in the country.
MedLink International, Inc. (OTCQB: MLKNA) (PINKSHEETS: MLKNA) Dear MedLink Shareholders: We continue to be optimistic for 2011.
Nationwide Health Properties, Inc. (NYSE: NHP) announced today that its Board of Directors has authorized a prorated dividend on NHP's common stock in connection with the completion of its pending merger with Ventas, Inc.
Neogen Corporation (NASDAQ:NEOG) announced today that it has acquired the assets of the VeroMara seafood testing laboratory from its parent company, GlycoMar Ltd.
Neuralstem, Inc. (NYSE Amex:CUR) announced that it has been approved to dose the final cohort in the ongoing Phase Ia trial to test the safety of NSI-189 for the treatment of major depression.
Panacea Global Inc., (OTCQB: PANG), a biopharmaceutical company specializing in blood (protein), serum and tissue tests to diagnose and monitor cancer, today announced the change of the Company's official trading symbol from MLXG to PANG.
PROLOR Biotech, Inc. (NYSE Amex:PBTH), today announced that its paediatric investigation plan for clinical development of its long-acting human growth hormone (hGH-CTP) has been accepted for review by the Paediatric Committee of the European Medicines Agency (EMA).
Rural/Metro Corporation (NASDAQ: RURL), a leading national provider of ambulance and private fire protection services, announced today that it has finalized a new contract to continue as the City of San Diego's exclusive provider of emergency ambulance services through June 2013.
Simulated Environment Concepts (SMEV.PK), the manufacturer and developer of medical, aesthetic, weight loss, wellness, and slimming equipment, announced today that the company has been invited to present at the National Eagles and Angels Association's (NEAA) New York City Chapter meeting, tomorrow, Tuesday, June 21, 2011, at the prestigiously renowned Oak Room (Plaza Hotel).
Therma-Med, Inc. (PINKSHEETS: THRA) ("the Company") is pleased to announce that it has compiled all the historical data and relevant information necessary to implement a successful field exploration program.
University General Health System, Inc. (OTCQB: UGHS) (PINKSHEETS: UGHS), a diversified, integrated, multi-specialty health care provider, today announced that it has retained RJ Falkner & Company, Inc. to develop and implement a comprehensive investor relations program for the Company.
Watson Pharmaceuticals, Inc. (NYSE:WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Dutasteride Capsules, 0.5 mg.